Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024
Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21 – 24, 2024 in Orlando, FL.
Terns Pharmaceuticals, Inc.（“Terns”或“公司”）（纳斯达克：TERN）是一家临床阶段的生物制药公司，开发一系列小分子药物候选产品以治疗严重疾病，包括肿瘤和肥胖症。今天宣布，在2024年6月21日至24日于佛罗里达州奥兰多举行的美国糖尿病协会（ADA）第84届科学会议上，将重点展示支持联合GLP-1受体激动剂治疗肥胖症的高度选择性甲状腺激素受体β（THR-β）受体激动剂TERN-501的临床前数据的海报报告。